Effect of methotrexate on serum levels of IL-22 in patients with psoriasis

Meephansan, Jitlada; Ruchusatsawat, Kriangsak; Sindhupak, Wannasri; Thorner, Paul; Wongpiyabovorn, Jongkonnee

doi:10.1684/ejd.2011.1335

Cited by 41 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Thus, it is possible that reduced levels of IL-17 and 23 may result from the anti-inflammatory effects of MTX [10]. The present study presents evidence for a novel therapeutic mechanism of methotrexate in psoriasis via reduction of serum IL-17 and IL-23.…”

Section: Discussionmentioning

confidence: 56%

“…However, this does not fully explain the effectiveness of MTX in psoriasis. In vitro studies have suggested that MTX has an anti-inflammatory effects through induction of immune cell apoptosis and inhibition of T-cell activation [10]. …”

Section: Discussionmentioning

confidence: 99%

“…However, in patients with psoriasis, Meephansan et al, 2011 [10], showed that MTX significantly reduced serum level of IL-22 and there was a positive correlation between IL-22 levels and psoriasis area and severity index (PASI) score. To our knowledge, there are no studies in the literature, particularly in Egyptian psoriatic patients, comparing the effects of NB-UVB and MTX, on the serum levels of IL-17 and IL-23.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis

Elghandour

Youssef

Aly³

et al. 2013

Dermatology Research and Practice

View full text Add to dashboard Cite

Background. There is raised interest in the involvement of interleukin-(IL-)23/T-helper 17 cells (Th17) axis in the pathogenesis of psoriasis. Objectives. To compare the effect of narrow band ultraviolet B (NB-UVB) and methotrexate (MTX) therapy on serum levels of IL-17 and IL-23 in psoriatic patients. Methods. Thirty patients with severe plaque psoriasis were included: 15 patients received NB-UVB three times weekly (group I) and 15 patients received MTX 0.3 mg/kg per week (group II), both for 8 weeks. Before and after treatment, serum levels of IL-17 and IL-23 were investigated by ELISA technique and psoriasis area and severity index (PASI) was calculated. Results. After treatment, all patients showed a reduction in their PASI score, IL-17 and IL-23 serum levels with a nonsignificant difference between both therapeutic modalities (P value >0.05). A positive correlation was detected between the percent of reduction of IL-17, IL-23 and the percent of reduction of PASI score for patients receiving both treatments. No correlation was found between the percent of reduction of IL-17, IL-23 and duration of disease or age of all patients in this study. Conclusion. Interleukin-17 and IL-23 serum level may serve as a potential biomarker for predicting the prognosis and therapeutic response of NB-UVB or MTX in treating psoriasis.

show abstract

Section: Discussionmentioning

confidence: 56%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis

Elghandour

Youssef

Aly³

et al. 2013

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…At the molecular and cellular level, MTX can down-regulate expression of chemokine CCL20 and cytokine IL22 in Th1, Th17 and Th22 cells, in patients with psoriasis19. Consistently, MTX significantly reduces serum IL-22 level in psoriasis34. LEF is an isoxazole derivative that critically controls the de novo synthesis of pyrimidine ribonucleotide uridine monophosphate35.…”

Section: Discussionmentioning

confidence: 98%

IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide

Wang

Zhao

Liu

et al. 2017

Sci Rep

View full text Add to dashboard Cite

T cells are key players in immune-mediated rheumatoid arthritis (RA). We previously reported that interleukin (IL)-22+CD4+T helper (IL-22+ Th) cells and IL-22 critically control the pathogenesis of RA. Here we monitored circulating levels of different IL-22+ Th cell subsets and measured plasma levels of IL-22, IL-17, and interferon (IFN)-γ in 60 patients with active RA following 12-week combination methotrexate (MTX) and leflunomide (LEF) therapy (MTX+LEF) and 20 healthy individuals. We found the frequencies of circulating IFN-γ−IL-17−IL-22+ (Th22), IFN-γ−IL-17+ (total Th17), IFN-γ+IL-17−IL-22+ (IL-22+Th1) cells, and IFN-γ−IL-17+IL-22+ (IL-22+Th17) cells, as well as the plasma levels of IL-22, IL-17 and IFN-γ to be significantly reduced in RA patients that responded to treatment, but not in non-responders. Reductions in plasma IL-22 level significantly correlated with percentage of circulating Th22 cells and the decrease of plasma IL-22 level correlated with the reduction of DAS28 in responders. Our data suggests that circulating Th22 cells and plasma IL-22 level play a detrimental role in RA. The combination MTX+LEF therapy, by targeting Th22 cells and reducing IL-22 level, relieves the immune defects and ameliorates symptoms of RA. This study provides novel mechanistic understanding of the pathogenesis of RA, which may promote a design of better therapies for RA.

show abstract

“…Interestingly, each protein was associated with corresponding increases in messenger RNA (mRNA) levels in psoriatic skin lesions. High mRNA and protein levels of IL-22 are also detected and they decrease after successful therapy 32 33. Despite the important role of Th17 cells in psoriasis, IL-17A serum levels are not consistently found to be increased in different cohorts of psoriatic patients possibly due to low levels and sensitivity issues of the detection assays 30 31 33.…”

Section: Blood Biomarkersmentioning

confidence: 99%

Biomarkers in psoriasis and psoriatic arthritis

Meglio²,

2013

View full text Add to dashboard Cite

Psoriasis is a common immune-mediated disease of the skin, which associates in 20-30% of patients with psoriatic arthritis (PsA). The immunopathogenesis of both conditions is not fully understood as it is the result of a complex interaction between genetic, environmental and immunological factors. At present there is no cure for psoriasis and there are no specific markers that can accurately predict disease progression and therapeutic response. Therefore, biomarkers for disease prognosis and response to treatment are urgently needed to help clinicians with objective indications to improve patient management and outcomes. Although many efforts have been made to identify psoriasis/PsA biomarkers none of them has yet been translated into routine clinical practice. In this review we summarise the different classes of possible biomarkers explored in psoriasis and PsA so far and discuss novel strategies for biomarker discovery.

show abstract

Effect of methotrexate on serum levels of IL-22 in patients with psoriasis

Cited by 41 publications

References 0 publications

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis

Effect of Narrow Band Ultraviolet B Therapy versus Methotrexate on Serum Levels of Interleukin-17 and Interleukin-23 in Egyptian Patients with Severe Psoriasis

IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide

Biomarkers in psoriasis and psoriatic arthritis

Contact Info

Product

Resources

About